IVERIC bio, Inc. (ISEE) financial statements (2020 and earlier)

Company profile

Business Address ONE PENN PLAZA
NEW YORK, NY 10119
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:126131167289297464
Cash and cash equivalents12613116713422240
Short-term investments   15575424
Other undisclosed cash, cash equivalents, and short-term investments  00  
Receivables1 1441
Deferred tax assets    0
Other undisclosed current assets223369
Total current assets:129133172296306473
Noncurrent Assets
Operating lease, right-of-use asset0
Nontrade receivables14    
Property, plant and equipment001332
Long-term investments and receivables    95 
Long-term investments    95 
Deposits noncurrent assets     0
Other noncurrent assets000000
Deferred tax assets, net   234
Other undisclosed noncurrent assets  4   
Total noncurrent assets:24441226
TOTAL ASSETS:130137176300429480
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:66812129
Other undisclosed accounts payable and accrued liabilities66812129
Debt0     
Deferred revenue and credits 773
Other undisclosed current liabilities77547198
Total current liabilities:131313663820
Noncurrent Liabilities
Liabilities, other than long-term debt   203206206
Deferred revenue and credits 203206206
Other undisclosed noncurrent liabilities  125125125125
Total noncurrent liabilities:  125328331331
Total liabilities:1313138394369351
Stockholders' equity
Stockholders' equity attributable to parent11712438(95)60129
Common stock000000
Additional paid in capital598546523505466428
Accumulated other comprehensive loss   (0)(0)(0)
Accumulated deficit(481)(422)(485)(599)(406)(300)
Total stockholders' equity:11712438(95)60129
TOTAL LIABILITIES AND EQUITY:130137176300429480

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:  210515241
Operating expenses(61)(65)(102)(246)(175)(122)
Operating income (loss):(61)(65)108(196)(124)(81)
Nonoperating income (expense)0(0)(0)00(2)
Investment income, nonoperating     (2)
Other nonoperating income (expense)0(0)(0)00 
Income (loss) from continuing operations before equity method investments, income taxes:(61)(65)108(196)(123)(83)
Other undisclosed income from continuing operations before income taxes21272212
Income (loss) from continuing operations before income taxes:(59)62109(194)(123)(80)
Income tax expense (benefit)015017(36)
Net income (loss) available to common stockholders, diluted:(59)63114(193)(106)(117)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(59)63114(193)(106)(117)
Comprehensive income (loss):(59)63114(193)(106)(117)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  00(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:(59)63114(193)(106)(117)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: